| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7947681 | BIOMARIN PHARM | Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring |
Nov, 2024
(6 months from now) | |
| USRE43797 | BIOMARIN PHARM | Methods of administering tetrahydrobiopterin |
Nov, 2024
(6 months from now) | |
| US7612073 | BIOMARIN PHARM | Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring |
Nov, 2024
(6 months from now) | |
| US7566714 | BIOMARIN PHARM | Methods and compositions for the treatment of metabolic disorders |
Nov, 2024
(6 months from now) | |
| US8067416 | BIOMARIN PHARM | Methods and compositions for the treatment of metabolic disorders |
Nov, 2024
(6 months from now) | |
| US9433624 | BIOMARIN PHARM | Methods and compositions for the treatment of metabolic disorders |
Nov, 2024
(6 months from now) | |
| US7727987 | BIOMARIN PHARM | Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride |
Nov, 2024
(6 months from now) | |
| US8318745 | BIOMARIN PHARM | Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride |
Nov, 2024
(6 months from now) | |
|
USRE43797 (Pediatric) | BIOMARIN PHARM | Methods of administering tetrahydrobiopterin |
May, 2025
(1 year, 23 days from now) | |
|
US7947681 (Pediatric) | BIOMARIN PHARM | Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring |
May, 2025
(1 year, 23 days from now) | |
|
US7566714 (Pediatric) | BIOMARIN PHARM | Methods and compositions for the treatment of metabolic disorders |
May, 2025
(1 year, 23 days from now) | |
|
US7612073 (Pediatric) | BIOMARIN PHARM | Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring |
May, 2025
(1 year, 23 days from now) | |
|
US7727987 (Pediatric) | BIOMARIN PHARM | Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride |
May, 2025
(1 year, 23 days from now) | |
|
US8067416 (Pediatric) | BIOMARIN PHARM | Methods and compositions for the treatment of metabolic disorders |
May, 2025
(1 year, 23 days from now) | |
|
US9433624 (Pediatric) | BIOMARIN PHARM | Methods and compositions for the treatment of metabolic disorders |
May, 2025
(1 year, 23 days from now) | |
|
US8318745 (Pediatric) | BIOMARIN PHARM | Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride |
May, 2025
(1 year, 23 days from now) | |
| US7566462 | BIOMARIN PHARM | Stable tablet formulation |
Nov, 2025
(1 year, 6 months from now) | |
| US8003126 | BIOMARIN PHARM | Stable tablet formulation |
Nov, 2025
(1 year, 6 months from now) | |
|
US8003126 (Pediatric) | BIOMARIN PHARM | Stable tablet formulation |
May, 2026
(2 years from now) | |
|
US7566462 (Pediatric) | BIOMARIN PHARM | Stable tablet formulation |
May, 2026
(2 years from now) | |
| US9216178 | BIOMARIN PHARM | Dry blend formulation of tetrahydrobiopterin |
Nov, 2032
(8 years from now) | |
|
US9216178 (Pediatric) | BIOMARIN PHARM | Dry blend formulation of tetrahydrobiopterin |
May, 2033
(9 years from now) | |
Kuvan is owned by Biomarin Pharm.
Kuvan contains Sapropterin Dihydrochloride.
Kuvan has a total of 22 drug patents out of which 0 drug patents have expired.
Kuvan was authorised for market use on 13 December, 2007.
Kuvan is available in powder;oral, tablet;oral dosage forms.
Kuvan can be used as method of use for reducing blood phenylalanine levels in a human suffering from hyperphenylalaninemia, to reduce blood phenylalanine levels in patients with hyperphenylalaninemia due to tetra hydrobiopterin responsive phenylketonuria. kuvan should be taken orally with food to increase absorption, kuvan is indicated to reduce blood phenylalanine levels in patients with hyperphenylalaninemia, to reduce blood phenylalanine (phe) levels in patients with hyperphenylalaninemia (hpa).
Drug patent challenges can be filed against Kuvan from 23 October, 2016.
The generics of Kuvan are possible to be released after 01 May, 2033.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Apr 23, 2017 |
| Pediatric Exclusivity(PED) | Oct 23, 2017 |
| Orphan Drug Exclusivity(ODE) | Dec 13, 2014 |
| New Chemical Entity Exclusivity(NCE) | Dec 13, 2012 |
Drugs and Companies using SAPROPTERIN DIHYDROCHLORIDE ingredient
NCE-1 date: 23 October, 2016
Market Authorisation Date: 13 December, 2007
Treatment: To reduce blood phenylalanine (phe) levels in patients with hyperphenylalaninemia (hpa); Kuvan is indicated to reduce blood phenylalanine levels in patients with hyperphenylalaninemia; To reduce blood...
Dosage: TABLET;ORAL; POWDER;ORAL
KUVAN family patents
